• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

    5/7/24 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email

    Highlights:

    • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.
    • First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improved significantly from $55 million and $(19) million, respectively, in the first quarter of 2023.
    • First quarter GAAP earnings per share and adjusted earnings per share of $(0.29) and $(0.01), respectively, improved significantly as compared to $(0.67) and $(0.21), respectively, in the first quarter of 2023.
    • On May 6, announced the reorganization of its European operations and sale of its EndoPredict business, while retaining U.S. EndoPredict licensing rights.
    • Reiterates 2024 financial guidance issued on February 27, 2024.

    SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2024 and reiterated its previously issued outlook on business performance for the full-year 2024.

    "Myriad Genetics entered 2024 with positive momentum as we generated double digit revenue growth over the prior year period, significantly improved year-over-year net loss, and achieved positive adjusted EBITDA in the first quarter," said Paul J. Diaz, President and CEO of Myriad Genetics. "First quarter saw early indications of market share gains in hereditary cancer and prenatal testing and we expect this trend to accelerate as we move through the year. In addition, first quarter average revenue per test across our product portfolio benefited from expanded coverage and our ongoing efforts in revenue cycle management. We also remain optimistic about the evolution of our product portfolio as we continue to produce additional clinical validation studies and move closer to the launch of our new products. At the same time, we continue to advance a number of enhancements to improve access and ease of use for our customers, including electronic medical record (EMR) integrations and make meaningful progress in our Labs of the Future initiative. Myriad Genetics is growing, delivering improved financial results, and is continuing to invest in the innovation required to achieve our Mission and Vision to reach more patients with life-saving precision medicine."

    Financial and Operational Highlights:

    • Test volumes of 381,000 in the first quarter of 2024 increased 9% year-over-year.
    • The following table summarizes year-over-year testing volume changes in the company's core product categories:
     Three months ended  
     March 31, 2024 March 31, 2023

     % Change
    Product volumes:       
    Hereditary cancer71,149  65,484  9%
    Tumor profiling13,602  16,154  (16)%
    Prenatal171,857  158,020  9%
    Pharmacogenomics124,067  109,695  13%
    Total380,675  349,353  9%
     
    • The following table summarizes year-over-year revenue changes in the company's core product categories:
     Three months ended
    (in millions)March 31, 2024 March 31, 2023 % Change
    Product revenues:         
    Hereditary cancer$88.1  $75.7  16%
    Tumor profiling 30.9   37.3  (17)%
    Prenatal 44.3   36.2  22%
    Pharmacogenomics 38.9   32.0  21%
    Total$202.2  $181.2  12%
     
    • Gross margin of 68.1% in the first quarter of 2024 increased 70 basis points year-over-year, reflecting operating leverage and improved ASPs. Adjusted gross margin in the first quarter of 2024 was 68.5%, an increase of 80 basis points year-over-year.
    • First quarter of 2024 operating expenses were $165.5 million, while adjusted operating expenses were $139.1 million.
    • Operating loss in the first quarter of 2024 was $27.9 million, improving $24.3 million year-over-year; adjusted operating loss in the first quarter of 2024 was $0.6 million, improving $21.3 million year-over-year.

    Business Performance and Highlights:

    Oncology

    The Oncology business delivered revenue of $79.4 million in the first quarter of 2024.

    • First quarter 2024 hereditary cancer testing volumes and revenue in Oncology grew 10% and 20% year-over-year, respectively, reflecting market share gains, and ongoing initiatives to improve average revenue per test.
    • Prolaris first quarter 2024 revenue grew 9% year-over-year, benefiting, in part, from improved payer coverage.
    • First quarter 2024 tumor profiling testing revenue of $30.9 million, decreased 17% year-over-year, reflecting, to a large degree, a strong contribution from biopharma in the year ago period.
    • Established a research collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of MRD testing using Myriad Genetics' highly-sensitive test, Precise MRD.
    • Advanced the integration of the recently acquired CLIA-certified laboratory and Precise Tumor and Liquid assays from Intermountain Precision Genomics.
    • Today announced the reorganization of its European operations and sale of its EndoPredict business to Eurobio Scientific, while retaining a license to produce and sell EndoPredict in the U.S., to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the U.S.; Myriad will also license to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.

    Women's Health

    The Women's Health business delivered revenue of $83.9 million in the first quarter of 2024.

    • First quarter 2024 hereditary cancer testing volumes and revenue in Women's Health grew 7% and 12% year-over-year, respectively.
    • Prenatal testing volumes and revenue in the first quarter of 2024 grew 9% and 22% year-over-year, respectively, reflecting market share gains, and ongoing initiatives to improve average revenue per test.
    • In April 2024, Prenatal Diagnosis published a study demonstrating exceptional positive predictive value for 22q11.2 microdeletion screening using Myriad's prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. The American College of Medical Genetics and Genomics recently recommended that 22q11.2 screening be offered to all pregnant patients.

    Pharmacogenomics

    In the pharmacogenomics category, GeneSight test revenue was $38.9 million in the first quarter of 2024.

    • First quarter 2024 GeneSight testing volumes and revenue grew 13% and 21% year-over-year, respectively, reflecting ongoing initiatives to improve average revenue per test.
    • On April 8, 2024, study results presented at the American Association of Psychiatric Pharmacists (AAPP) conference indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test.

    Financial Guidance

    Myriad Genetics does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, real estate optimization and transformation initiatives, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and its impact on GAAP performance could vary materially.

    Below is a table summarizing Myriad Genetics' fiscal year 2024 financial guidance*:

    (in millions, except per share amounts)FY 2024 Expected Year-

    Over-Year Change
        
    Revenue$820 - $840 9% - 11%
    Gross margin %69.5% - 70.5% 50 - 150 bps
    Adjusted OPEX$572 - $582 5% - 7%
    Adjusted EBITDA**$20 - $30 $31 - $41
    Adjusted EPS***$0.00 - $0.05 $0.27 - $0.32
    *Assumes currency rates as of May 7, 2024
    ** Adjusted EBITDA is defined as Net Income (loss) plus income tax expense (benefit), total other income (expense), non-cash operating expenses, such as amortization of intangible assets, depreciation, impairment of long-lived assets, and share-based compensation expense, and one-time expenses such as expenses from real estate optimization initiatives, transformation initiatives, legal settlements, and divestitures and acquisitions.
    *** Full-year 2024 adjusted EPS is based on a 90 million share count.
     

    These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release.

    Conference Call and Webcast

    A conference call will be held today, Tuesday, May 7, 2024, at 4:30 p.m. EDT to discuss Myriad Genetics' financial results and business developments for the first quarter 2024. A live webcast of the conference call can be accessed on Myriad Genetics' Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register at https://register.vevent.com/register/BIa6e5709e0e9d43a6a8b0070d0b806384. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com.

    About Myriad Genetics

    Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

    Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, ColarisAP, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, Mygenehistory, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are registered trademarks or trademarks of Myriad Genetics, Inc.. All third-party marks—® and ™—are the property of their respective owners. © 2024 Myriad Genetics, Inc. All rights reserved.

    Revenue by Product (Unaudited):

     Three months ended March 31
    (in millions)2024 2023  
     WHONCPGxTotal WHONCPGxTotal % Change
    Hereditary Cancer$39.6 $48.5 $— $88.1  $35.3 $40.4 $— $75.7  16%
    Tumor Profiling —  30.9  —  30.9   —  37.3  —  37.3  (17)%
    Prenatal 44.3  —  —  44.3   36.2  —  —  36.2  22%
    Pharmacogenomics —  —  38.9  38.9   —  —  32.0  32.0  22%
    Total Revenue$83.9 $79.4 $38.9 $202.2  $71.5 $77.7 $32.0 $181.2  12%
                                 

    Business Units:

    WH = Women's Health

    ONC = Oncology

    PGx = Pharmacogenomics

    Product Categories:

    Hereditary Cancer – MyRisk, BRACAnalysis, BRACAnalysis CDx

    Tumor Profiling – myChoice CDx, Prolaris, Precise Tumor, EndoPredict

    Prenatal – Foresight, Prequel, SneakPeek

    Pharmacogenomics – GeneSight

     
    MYRIAD GENETICS, INC.

    AND SUBSIDIARIES

    Condensed Consolidated Statements of Operations

    (in millions, except per share amounts)
     
     Three months ended

    March 31,
     2024 2023
     (unaudited)
    Testing revenue$202.2  $181.2 
    Costs and expenses:   
    Cost of testing revenue 64.6   59.2 
    Research and development expense 24.9   22.5 
    Selling, general, and administrative expense 140.6   151.7 
    Total costs and expenses 230.1   233.4 
    Operating loss (27.9)  (52.2)
    Other income (expense):   
    Interest income 0.6   0.7 
    Interest expense (0.5)  (0.5)
    Other 1.9   (0.6)
    Total other income (expense), net 2.0   (0.4)
    Loss before income tax (25.9)  (52.6)
    Income tax expense 0.1   2.1 
    Net loss$(26.0) $(54.7)
    Net loss per share:   
    Basic and diluted$(0.29) $(0.67)
    Weighted average shares outstanding:   
    Basic and diluted 89.9   81.3 
            



    MYRIAD GENETICS, INC.

    AND SUBSIDIARIES

    Condensed Consolidated Balance Sheets

    (in millions, except share information)
     
     March 31,

    2024
     December 31,

    2023
     (unaudited)  
    ASSETS   
    Current assets:   
    Cash and cash equivalents$96.9  $132.1 
    Marketable investment securities 7.4   8.8 
    Trade accounts receivable 118.1   114.3 
    Inventory 24.6   22.0 
    Prepaid taxes 18.4   17.0 
    Prepaid expenses and other current assets 24.9   19.4 
    Total current assets 290.3   313.6 
    Operating lease right-of-use assets 58.9   61.6 
    Property, plant and equipment, net 118.5   119.0 
    Intangibles, net 340.9   349.5 
    Goodwill 287.0   287.4 
    Other assets 14.9   15.4 
    Total assets$1,110.5  $1,146.5 
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    Current liabilities:   
    Accounts payable 33.1   25.8 
    Accrued liabilities 99.2   113.9 
    Current maturities of operating lease liabilities 13.8   16.2 
    Total current liabilities 146.1   155.9 
    Unrecognized tax benefits 30.8   30.2 
    Long-term debt 38.7   38.5 
    Noncurrent operating lease liabilities 94.3   97.4 
    Other long-term liabilities 40.6   41.3 
    Total liabilities 350.5   363.3 
    Commitments and contingencies   
    Stockholders' equity:   
    Common stock, 90.5 million and 89.9 million shares outstanding at March 31, 2024 and December 31, 2023, respectively 0.9   0.9 
    Additional paid-in capital 1,418.8   1,415.5 
    Accumulated other comprehensive loss (4.2)  (3.7)
    Accumulated deficit (655.5)  (629.5)
    Total stockholders' equity 760.0   783.2 
    Total liabilities and stockholders' equity$1,110.5  $1,146.5 
            



    MYRIAD GENETICS, INC.

    AND SUBSIDIARIES

    Condensed Consolidated Statements of Cash Flows

    (in millions)
     
     Three months ended

    March 31,
     2024 2023
    Net cash used in operating activities$(18.6) $(33.2)
    Net cash provided by (used in) investing activities (7.1)  34.6 
    Net cash used in financing activities (8.8)  (4.9)
    Effect of foreign exchange rates on cash, cash equivalents, and restricted cash (0.8)  0.2 
    Net increase (decrease) in cash, cash equivalents, and restricted cash (35.3)  (3.3)
    Cash, cash equivalents, and restricted cash at beginning of the period 140.9   66.4 
    Cash, cash equivalents, and restricted cash at end of the period$105.6  $63.1 
            

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the company's fiscal year 2024 financial guidance, the company's plans to continue to produce additional clinical validation studies and move closer to the launch of new products, statements relating to the company's advancement of a number of enhancements to improve access and ease of use for customers, including EMR integrations, and that the company is growing, delivering improved financial results and is continuing to invest in the innovation required to achieve its Mission and Vision to reach more patients with life-saving precision medicine. These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

    These risks include, but are not limited to: the risk that sales and profit margins of the company's existing tests may decline; the risk that the company may not be able to operate its business on a profitable basis; risks related to the company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers' coverage and reimbursement levels for the company's tests or the company's ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the company may not successfully develop new markets or channels for its tests; the risk that licenses to the technology underlying the company's tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the company's laboratory testing facilities and the transition of such facilities to the company's new laboratory testing facilities; risks related to public concern over genetic testing in general or the company's tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the company's ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the company's ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; the risk that the company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if it all; risks related to the company's projections or estimates about the potential market opportunity for the company's current and future products; the risk that the company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the company's tests; the risk of patent-infringement claims or challenges to the validity of the company's patents; risks related to changes in intellectual property laws covering the company's tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks; risks of new, changing and competitive technologies in the United States and internationally and that the company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the company may be unable to comply with financial or operating covenants under the company's credit or lending agreements; the risk that the company may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of the company's insurance coverage limits and scope of insurance coverage with respect thereto; and other factors discussed under the heading "Risk Factors" contained in Item 1A of the company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad Genetics is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

    Statement regarding use of non-GAAP financial measures

    In this press release, the company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the schedules below and a description of the adjustments made to the GAAP financial measures is included at the end of the schedules.

    The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. 

    The company does not forecast GAAP operating expenses, net income (loss) or earnings per share because it cannot predict certain elements that are included in reported GAAP results.   Please see above under "Financial Guidance" for a full explanation.

    Reconciliation of GAAP to Non-GAAP Financial Measures

    for the Three Months Ended March 31, 2024 and 2023

    (unaudited data in millions, except per share amounts)

     Three months ended

    March 31,
     2024 2023
    Adjusted Gross Margin   
    GAAP Gross Profit (1)$137.6  $122.0 
    Acquisition - amortization of intangible assets 0.3   0.3 
    Equity compensation 0.3   0.3 
    Other adjustments 0.3   — 
    Adjusted Gross Profit$138.5  $122.6 
    Adjusted Gross Margin 68.5%  67.7%
    (1) Consists of total revenues less cost of testing revenue from the Condensed Consolidated Statements of Operations.
        
     Three months ended

    March 31,
     2024 2023
    Adjusted Operating Expenses   
    GAAP Operating Expenses (1)$165.5  $174.2 
    Acquisition - amortization of intangible assets (10.4)  (10.3)
    Equity compensation (11.6)  (7.1)
    Real estate optimization (1.2)  (7.5)
    Transformation initiatives (1.9)  (4.1)
    Legal charges, net of insurance reimbursement 0.1   (0.3)
    Other adjustments (1.4)  (0.4)
    Adjusted Operating Expenses$139.1  $144.5 
    (1) Consists of research and development expense and selling, general and administrative expense from the Condensed Consolidated Statements of Operations.
        
        
     Three months ended

    March 31,
     2024 2023
    Adjusted Operating Income (Loss)   
    GAAP Operating Loss$(27.9) $(52.2)
    Acquisition - amortization of intangible assets 10.7   10.6 
    Equity compensation 11.9   7.4 
    Real estate optimization 1.2   7.5 
    Transformation initiatives 1.9   4.1 
    Legal charges, net of insurance reimbursement (0.1)  0.3 
    Other adjustments 1.7   0.4 
    Adjusted Operating Loss$(0.6) $(21.9)
        
     Three months ended

    March 31,
     2024 2023
    Adjusted Net Income (Loss) (1)   
    GAAP Net Loss$(26.0) $(54.7)
    Acquisition - amortization of intangible assets 10.7   10.6 
    Equity compensation 11.9   7.4 
    Real estate optimization 1.2   7.5 
    Transformation initiatives 1.9   4.1 
    Legal charges, net of insurance reimbursement (0.1)  0.3 
    Other adjustments 0.2   0.4 
    Tax adjustments (0.3)  7.0 
    Adjusted Net Loss$(0.5) $(17.4)
    Weighted average shares outstanding:   
    Basic 89.9   81.3 
    Diluted 89.9   81.3 
    Adjusted Earnings Per Share   
    Basic$(0.01) $(0.21)
    Diluted$(0.01) $(0.21)
    (1) To determine Adjusted Earnings (Loss) Per Share, or adjusted EPS.
     



     Three months ended

    March 31,
     2024 2023
    Adjusted EBITDA   
    GAAP Net Loss$(26.0) $(54.7)
    Acquisition - amortization of intangible assets 10.7   10.6 
    Depreciation expense 4.5   3.0 
    Equity compensation 11.9   7.4 
    Real estate optimization(1) 1.2   7.5 
    Transformation initiatives 1.9   4.1 
    Legal charges, net of insurance reimbursement (0.1)  0.3 
    Interest expense, net of interest income(2) (0.1)  (0.2)
    Other adjustments (0.1)  1.2 
    Income tax expense 0.1   2.0 
    Adjusted EBITDA$4.0  $(18.8)
    (1) Real estate optimization includes $0.5 million and $5.8 million of depreciation expense for the three months ended March 31, 2024 and 2023, respectively.
    (2) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations.
     

    Adjusted Free Cash Flow Reconciliation

    for the Three Months Ended March 31, 2024 and 2023

    (unaudited data in millions)

     Three months ended

    March 31,
     2024 2023
    Cash flow from operations$(18.6) $(33.2)
    Real estate optimization 6.2   1.8 
    Transformation initiatives 1.9   4.1 
    Legal charges, net of insurance reimbursement —   1.8 
    Other adjustments 1.2   0.4 
    Adjusted operating cash flow$(9.3) $(25.1)
    Capital expenditures (6.7)  (23.5)
    Capitalization of internal-use software costs (1.9)  — 
    Adjusted free cash flow$(17.9) $(48.6)
            

    Following is a description of the adjustments made to GAAP financial measures:

    • Acquisition – amortization of intangible assets – represents recurring amortization charges resulting from the acquisition of intangible assets.
    • Equity compensation – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
    • Real estate optimization – costs related to real estate initiatives. Prior to the fourth quarter 2023 reporting period, these costs were included in the transformation initiatives category. With respect to the adjusted free cash flow reconciliation, the cash flow effect of real estate optimizations excludes non-cash items such as accelerated depreciation. These costs include the following:
      • For the three months ended March 31, 2024, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South Francisco, California, while maintaining our current laboratories in those locations, costs associated with the voluntary termination of a lease, testing and set-up costs for equipment in our new facilities, and impairment in connection with the ceased use of one of our facilities.
      • For the three months ended March 31, 2023, additional rent as a result of the build-out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our current laboratories in those locations, and accelerated depreciation in connection with our decision to cease the use of our former corporate headquarters in Salt Lake City, Utah.
    • Transformation initiatives – costs related to transformation initiatives including:
      • For the three months ended March 31, 2024, consulting and professional fees.
      • For the three months ended March 31, 2023, consulting and professional fees and severance costs related to restructuring.
    • Legal charges, net of insurance reimbursement – one-time legal expenses, net of insurance reimbursement. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes cash paid for settlements in the related period.
    • Other adjustments – other one-time non-recurring expenses including:
      • For the three months ended March 31, 2024, primarily includes a gain recognized on acquisition, changes in the fair value of contingent consideration related to acquisitions from prior years, the reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity, and costs incurred in connection with executive personnel changes.
      • For the three months ended March 31, 2023, primarily includes consulting and professional fees and changes in the fair value of contingent consideration related to acquisitions from prior years.
      • For purposes of adjusted EBITDA, other adjustments include the items listed above as well as amounts included in Other income/expense in the financial statements.
    • Depreciation expense - depreciation expense recognized on our fixed assets.
    • Tax adjustments – tax expense/(benefit) due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States.
      • As of March 31, 2024, a valuation allowance of $57.0 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.
      • As of March 31, 2023, a valuation allowance of $11.6 million was not recognized for non-GAAP purposes given our historical and forecasted positive earnings performance.
      • For purposes of adjusted EBITDA, the income tax expense adjustment includes the income tax expense (benefit) recognized in the financial statements.
        
    Media Contact:Megan ManzariInvestor Contact:Matt Scalo
     (385) 318-3718 (801) 584-3532
     [email protected] [email protected]
        


    Primary Logo

    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    9/19/2024$32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commerical Officer Donnelly Brian J was granted 397,534 shares (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/2/25 4:15:16 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Donnelly Brian J

      3 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:29:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Verratti Mark

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:27:14 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

      SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer. The study, "Association of Polygenic

      5/7/25 4:30:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

      SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. "It's encouraging to

      4/30/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myriad Genetics Inc.

      10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 8:48:53 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 4:08:36 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Myriad Genetics Inc.

      S-8 - MYRIAD GENETICS INC (0000899923) (Filer)

      5/1/25 4:03:06 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

      4/29/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

      2/18/25 8:30:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myriad Genetics downgraded by Wolfe Research

      Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

      5/8/25 8:27:12 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

      5/7/25 8:36:31 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Guggenheim

      Guggenheim downgraded Myriad Genetics from Buy to Neutral

      4/9/25 8:36:07 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

      SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

      11/14/24 4:16:31 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      5/1/24 4:21:33 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      4/25/24 4:18:40 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

      SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

      4/7/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Announces Senior Leadership Transition

      SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

      2/24/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances